Tryptamine Therapeutics (ASX:TYP) Interest Expense : A$-0.19 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Tryptamine Therapeutics's interest expense for the six months ended in Dec. 2023 was A$ -0.05 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.19 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Tryptamine Therapeutics's Operating Income for the six months ended in Dec. 2023 was A$ -1.93 Mil. Tryptamine Therapeutics's Interest Expense for the six months ended in Dec. 2023 was A$ -0.05 Mil. Tryptamine Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Tryptamine Therapeutics Interest Expense Historical Data

The historical data trend for Tryptamine Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Interest Expense Chart

Tryptamine Therapeutics Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Interest Expense

Get a 7-Day Free Trial

-0.08

-0.33

Tryptamine Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial						-	-0.08	-0.19	-0.14	-0.05

Tryptamine Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.19 Mil.

Tryptamine Therapeutics (ASX:TYP) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Tryptamine Therapeutics's Interest Expense for the six months ended in Dec. 2023 was A$-0.05 Mil. Its Operating Income for the six months ended in Dec. 2023 was A$-1.93 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was A$0.00 Mil.

Tryptamine Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Tryptamine Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Tryptamine Therapeutics (ASX:TYP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124

Website

https://www.exopharm.com

Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines